Accessibility Menu
BriaCell Therapeutics logo

BriaCell Therapeutics(NASDAQ) BCTX

Current Price$3.58
Market Cap$32.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 YearN/A
1 Year-55%
1 Month+24%
BriaCell Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.722026-07-23
BriaCell Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.38%USD 3.852026-07-16
1 month+24.41%USD 2.992026-06-23
3 month-4.12%USD 3.882026-04-24
Year to date-47.68%USD 7.112025-12-31
1 year-55.18%USD 8.302025-07-23
Since inception-99.93%USD 5,715.062014-12-15

BriaCell Therapeutics Financials at a Glance

Market Cap

$32.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$37.06M

EPS (TTM)

-$12.21

P/E Ratio

-0.30

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$3.58

Volume

63,886.792

Open

$3.72

Previous Close

$3.58

Daily Range

$3.50 - $3.72

52-Week Range

$2.60 - $14.68

Estimated Earnings Date

Jun 9, 2026

BCTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BriaCell Therapeutics

BriaCell develops cancer treatments that help the immune system fight tumors. Its main focus is breast cancer therapies for patients with advanced disease. The company also works on tests to match patients with the right treatment.

Lab Bench to Bedside: What BriaCell Sells

  • Bria-IMT: Lead immunotherapy for advanced breast cancer, currently in a pivotal Phase 3 clinical study. (0% of revenue; pre-commercial)
  • Bria-OTS: Personalized, off-the-shelf immunotherapy for breast cancer, in early clinical testing. (0% of revenue)
  • BriaDx: Diagnostic test to help select and monitor patients for BriaCell therapies. (0% of revenue)
  • BriaPro: Subsidiary developing antibody and cell therapy platforms for future cancer treatments. (0% of revenue)
  • PKCδ Inhibitors: Early-stage drug candidates for cancer, managed by BriaPro. (0% of revenue)

Growth Spurts and Strategic Moves

  • Launched pivotal Phase 3 trial for Bria-IMT in 2024.
  • Started Phase 1/2a trial for Bria-OTS in 2024.
  • Formed supply partnerships with Incyte (Retifanlimab) and BeiGene (tislelizumab) in 2024-2025.
  • Spun out BriaPro Therapeutics for antibody and cell therapy development in 2023.
  • Raised $35.9 million in gross proceeds through public and direct offerings between September 2024 and April 2025.

Why BriaCell Catches the Eye

BriaCell focuses on immunotherapies that use the body’s own defenses to fight cancer. Its approach includes both ready-made and personalized treatments, plus diagnostic tools to match patients with therapies. The company partners with larger drug makers to access key medicines for its trials.

Five Things You Need to Know

  • No revenue reported for 2023-2025; company is pre-commercial.
  • Operating loss was $18,650,530 for the nine months ended April 30, 2025, down 32.3% year-on-year.
  • Research and development expenses fell 37.8% to $14,160,314 for the nine months ended April 30, 2025.
  • Cash and cash equivalents were $12,460,253 as of April 30, 2025, up from $862,089 in July 2024.

Bottom Line

BriaCell remains a clinical-stage company focused on cancer immunotherapies. Its future depends on successful trials and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

William V. Williams, MD

Website

www.briacell.com

Headquarters

West Vancouver, BC V7T 2X1, CA

BCTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-147.92%

Return on Capital

-153.48%

Return on Assets

-113.23%

Earnings Yield

-3.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.70M

Volume

63.89K

Avg. Volume

202.86K

Financials (TTM)

Gross Profit

-$89.96K

Operating Income

-$38.64M

EBITDA

-$38.10M

Operating Cash Flow

-$36.94M

Capital Expenditure

-$129.18K

Free Cash Flow

-$37.07M

Cash & ST Invst.

$22.80M

Total Debt

$0.00

BriaCell Therapeutics Performance Analysis

BriaCell Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 0N/A
20232023-07-31USD 0N/A
20242024-07-31USD 0N/A
20252025-07-31USD 0N/A
BriaCell Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31N/A
Q12025-10-31N/A
Q22026-01-31N/A
Q32026-04-30N/A
BriaCell Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -259.83-43.3%
20232023-07-31USD -194.97-25.0%
20242024-07-31USD -43.68-77.6%
20252025-07-31USD -62.1942.4%
BriaCell Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-257.9%
Q12025-10-3125.9%
Q22026-01-3139.8%
Q32026-04-3061.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$32.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.02M

N/A

Employees

16

N/A

Net Income

-$7.16M

+15.4%

EBITDA

-$7.17M

+15.7%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$22.80M

+32.5%

Total Debt

$0.00

N/A

Accounts Receivable

$2.59M

-19.4%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.13%

N/A

Return on Invested Capital

-1.36%

N/A

Free Cash Flow

-$7.21M

+28.7%

Operating Cash Flow

-$7.08M

+30.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LPTXLeap Therapeutics, Inc.
$0.77-3.15%
ALLRAllarity Therapeutics, Inc.
$1.19-2.46%
ENTOEntero Therapeutics, Inc.
$2.85-5.00%
MBRXMoleculin Biotech, Inc.
$2.12+1.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TAT&T
$24.13+0.05%
FFord Motor Company
$14.37+0.02%

Questions About BCTX

What is the current price of BriaCell Therapeutics?

BriaCell Therapeutics is trading at $3.58 per share.

What is the 52-week range for BriaCell Therapeutics?

Over the past 52 weeks, BriaCell Therapeutics has traded between $2.60 and $14.68.

How much debt does BriaCell Therapeutics have?

As of the most recent reporting period, BriaCell Therapeutics reported total debt of $0.00.

How much cash does BriaCell Therapeutics have on hand?

BriaCell Therapeutics reported $6.88M in cash and cash equivalents in its most recent financial results.

What is BriaCell Therapeutics’s dividend yield?

BriaCell Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services